Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program

Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim. To assess the efficacy of PARP inhibitors in rea...

Descrición completa

Detalles Bibliográficos

Principais autores:	A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin
Formato:	Artigo
Idioma:	Russo
Publicado:	Remedium Group LLC 2022-06-01
Series:	Медицинский совет
Assuntos:	olaparib ovarian cancer brca maintenance therapy parp inhibitors clinical practice real-world evidence (rwe)
Acceso en liña:	https://www.med-sovet.pro/jour/article/view/6919
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!